{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.12","value":"15.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"Colorectal Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.00","value":"29.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Gastroesophageal Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"48.69","value":"21.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"title":"Non-Small Cell Lung Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.40","value":"22.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"title":"Ovarian Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.91","value":"12.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Prostate Cancer"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.67","value":"3.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Squamous Cell Carcinoma of Head and Neck"}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"}],"units":"Participants"}],"description":"The percent change in tumor size at its smallest size. The sum of diameters of target lesions was determined at each tumor assessment. The percent change is the smallest post-baseline sum divided by the baseline (pre-treatment) sum, multiplied by 100.","dispersionType":"Standard Deviation","groups":[{"description":"LY2523355: Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a one hour infusion on Days 1, 2 and 3 of a 21 day cycle for up to 2 cycles (4 cycles for prostate cancer participants). Additional cycles administered based on participant response assessment.\n\nPegfilgrastim: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer participants). Additional cycles of LY2523355 administered based on participant response assessment.","id":"OG000","title":"LY2523355"}],"paramType":"MEAN","populationDescription":"All enrolled participants who received at least 1 dose of study drug with results at baseline and at time of best response.","reportingStatus":"POSTED","timeFrame":"Baseline until cycle with maximum change from baseline up to 36 weeks","title":"Change in Tumor Size at Smallest Size (Best Response)","type":"SECONDARY","unitOfMeasure":"percentage of change"}